Synthesis and biological evaluation of novel 2-amino-3-aroyl-4-neopentyl-5- substituted thiophene derivatives as allosteric enhancers of the A1 adenosine receptor

Bioorganic and Medicinal Chemistry

Volumn 22, Issue 1, 2014, Pages 148-166

  Romagnoli, Romeo ^a   Baraldi, Pier Giovanni ^a   Carrion, Maria Dora ^a   Cruz Lopez, Olga ^a   Cara, Carlota Lopez ^a   Saponaro, Giulia ^a   Preti, Delia ^a   Tabrizi, Mojgan Aghazadeh ^a   Baraldi, Stefania ^a   Moorman, Allan R ^b   Vincenzi, Fabrizio ^a   Borea, Pier Andrea ^a   Varani, Katia ^a  

^a UNIVERSITY OF FERRARA   (Italy)

^b King Pharmaceuticals Inc   (United States)

Author keywords

2 Amino 3 benzoylthiophene; A1 adenosine receptor; Allosteric modulation; G protein coupled receptors

Indexed keywords

2 AMINO 3 AROYL 4 NEOPENTYLTHIOPHENE DERIVATIVE; 2 AMINO 4,5 DIMETHYL 3 (3 TRIFLUOROMETHYLBENZOYL)THIOPHENE; [2 AMINO 4 (2,2 DIMETHYLPROPYL) 5 (4 METHOXYPHENYL)THIOPHEN 3 YL](3 CHLOROPHENYL)METHANONE; [2 AMINO 4 (2,2 DIMETHYLPROPYL) 5 (4 METHOXYPHENYL)THIOPHEN 3 YL](3 TRIFLUOROMETHYLPHENYL)METHANONE; [2 AMINO 4 (2,2 DIMETHYLPROPYL) 5 (4 METHOXYPHENYL)THIOPHEN 3 YL](3,4 DICHLOROPHENYL)METHANONE; [2 AMINO 4 (2,2 DIMETHYLPROPYL) 5 (4 METHOXYPHENYL)THIOPHEN 3 YL](4 CHLOROPHENYL)METHANONE; [2 AMINO 4 (2,2 DIMETHYLPROPYL) 5 (4 METHOXYPHENYL)THIOPHEN 3 YL](4 METHYLPHENYL)METHANONE; [2 AMINO 4 (2,2 DIMETHYLPROPYL) 5 (FURAN 2 YL)THIOPHEN 3 YL](4 CHLOROPHENYL)METHANONE; [2 AMINO 4 (2,2 DIMETHYLPROPYL) 5 (FURAN 3 YL)THIOPHEN 3 YL](4 CHLOROPHENYL)METHANONE; [2 AMINO 4 (2,2 DIMETHYLPROPYL) 5 (PYRAZOL 4 YL)THIOPHEN 3 YL](4 CHLOROPHENYL)METHANONE; [2 AMINO 4 (2,2 DIMETHYLPROPYL) 5 (PYRIDINE 4 YL)THIOPHEN 3 YL](4 CHLOROPHENYL)METHANONE; [2 AMINO 4 (2,2 DIMETHYLPROPYL) 5 (THIOPHEN 2 YL)THIOPHEN 3 YL](4 CHLOROPHENYL)METHANONE; [2 AMINO 4 (2,2 DIMETHYLPROPYL) 5 (THIOPHEN 3 YL)THIOPHEN 3 YL](4 CHLOROPHENYL)METHANONE; [2 AMINO 4 (2,2 DIMETHYLPROPYL) 5 BROMOTHIOPHEN 3 YL](3 CHLOROPHENYL)METHANONE; [2 AMINO 4 (2,2 DIMETHYLPROPYL) 5 BROMOTHIOPHEN 3 YL](3 TRIFLUOROMETHYLPHENYL)METHANONE; [2 AMINO 4 (2,2 DIMETHYLPROPYL) 5 BROMOTHIOPHEN 3 YL](3,4 DICHLOROPHENYL)METHANONE; [2 AMINO 4 (2,2 DIMETHYLPROPYL) 5 BROMOTHIOPHEN 3 YL](4 CHLOROPHENYL)METHANONE; [2 AMINO 4 (2,2 DIMETHYLPROPYL) 5 BROMOTHIOPHEN 3 YL](4 METHYLPHENYL)METHANONE; [2 AMINO 4 (2,2 DIMETHYLPROPYL) 5 PHENYLTHIOPHEN 3 YL](2 CHLOROPHENYL)METHANONE; [2 AMINO 4 (2,2 DIMETHYLPROPYL) 5 PHENYLTHIOPHEN 3 YL](2,4 DICHLOROPHENYL)METHANONE; [2 AMINO 4 (2,2 DIMETHYLPROPYL) 5 PHENYLTHIOPHEN 3 YL](3 CHLOROPHENYL)METHANONE; [2 AMINO 4 (2,2 DIMETHYLPROPYL) 5 PHENYLTHIOPHEN 3 YL](3 TRIFLUOROMETHYLPHENYL)METHANONE; [2 AMINO 4 (2,2 DIMETHYLPROPYL) 5 PHENYLTHIOPHEN 3 YL](3,4 DICHLOROPHENYL)METHANONE; [2 AMINO 4 (2,2 DIMETHYLPROPYL) 5 PHENYLTHIOPHEN 3 YL](4 CHLOROPHENYL)METHANONE; [2 AMINO 4 (2,2 DIMETHYLPROPYL) 5 PHENYLTHIOPHEN 3 YL](4 METHYLPHENYL)METHANONE; [2 AMINO 5 (3,5 DIMETHYLISOXAZOL 4 YL) 4 (2,2 DIMETHYLPROPYL)THIOPHEN 3 YL](4 CHLOROPHENYL)METHANONE; ADENOSINE A1 RECEPTOR; ADENOSINE A1 RECEPTOR ANTAGONIST; THIOPHENE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALLOSTERISM; ARTICLE; BINDING AFFINITY; CHO CELL; CONTROLLED STUDY; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; RECEPTOR DENSITY;

[(3)H](4-(2-[7-AMINO-2-(2-FURIL)[1,2.4]TRIAZOLO[2,3-A][1,3,5]TRIAZIN-5-YLAMINO]ETHYL)PHENOL); [(3)H]5-N-(4-METHOXYPHENYLCARBAMOYL)AMINO-8-PROPYL-2-(2-FURYL)PYRAZOLO[4,3-E]-1,2,4-TRIAZOLO[1,5-C]PYRIMIDINE; 2-AMINO-3-BENZOYLTHIOPHENE; 2-CHLORO-N(6)-CYCLOPENTYLADENOSINE; A(1) ADENOSINE RECEPTOR; AE(S); ALLOSTERIC ENHANCER(S); ALLOSTERIC MODULATION; CAMP; CCPA; CENTRAL NERVOUS SYSTEM; CESIUM FLUORIDE; CHINESE HAMSTER OVARY; CHO; CNS; CSF; CYCLIC ADENOSINE MONOPHOSPHATE; ELECTRON-RELEASING GROUP; ELECTRON-WITHDRAWING GROUP; ERG; EWG; G PROTEIN-COUPLED RECEPTORS; GPCRS; HA(1)AR; HUMAN A(1) ADENOSINE RECEPTOR; N-BROMOSUCCINIMIDE; NBS; PDCL(2)(DPPF); [(3)H]1,3-DIPROPYL-8-CYCLOPENTYL-XANTHINE; [(3)H]2-CHLORO-N(6)-CYCLOPENTYLADENOSINE; [(3)H]CCPA; [(3)H]DPCPX; [(3)H]MRE-3008F20; [(3)H]ZM 241385; [1,1′-BIS(DIPHENYLPHOSPHINO)FERROCENE] DICHLOROPALLADIUM(II) COMPLEX WITH DICHLOROMETHANE;

ALLOSTERIC REGULATION; ANIMALS; CHO CELLS; CRICETINAE; CRICETULUS; HUMANS; RECEPTOR, ADENOSINE A1; STRUCTURE-ACTIVITY RELATIONSHIP; THIOPHENES;

EID: 84891482194     PISSN: 09680896     EISSN: 14643391     Source Type: Journal    
DOI: 10.1016/j.bmc.2013.11.043     Document Type: Article

References (50)

1. K.A. Jacobson, and Z.-G. Gao Nat. Rev. Drug Disc. 5 2006 247
2. B.B. Fredholm, A.P. Ijzerman, K.A. Jacobson, K.N. Klotz, and J. Linden Pharmacol. Rev. 53 2001 527
3. D.M. Van Calker, M. Muller, and B. Hamprecht J. Neurochem. 33 1979 999
4. K. Mubagwa, and W. Flameng Cardiovasc. Res. 52 2001 25
5. B.B. Fredholm Cell Death Differ. 14 2007 1315
6. B.B. Fredholm Int. Rev. Neurobiol. 40 1997 259
7. M.P. De Ninno Adenosine A. Doherty, Annual Reports in Medicinal Chemistry Vol. 33 1998 Academic press San Diego 1111
8. G.L. Stiles Adenosine Receptors Subtypes: New Insights From Cloning and Functional Studies K.A. Jacobson, M.F. Jarvis, Purinergic Approaches in Experimental Therapeutics 1997 Wiley-Liss New York 29
9. C. Russo, G. Arcidiacono, and R. Polosa Fundam. Clin. Pharmacol. 20 2006 9
10. A.K. Dhalla, J.C. Shryock, R. Shreeniwas, and L. Belardinelli Curr. Top. Med. Chem. 3 2003 369
11. K.A. Jacobson, Z.-G. Gao, A. Göblyös, and A.P. IJzerman Adv. Pharmacol. 61 2011 187
12. A. Göblyös, and A.P. IJzerman Biochim. Biophys. Acta 1808 2011 1309
13. L.T. May, K. Leach, P.M. Sexton, and A. Christopoulos Annu. Rev. Pharmacol. Toxicol. 47 2007 1
14. T.W. Schwartz, and B. Holst Trends Pharmacol. Sci. 28 2007 366
15. C. Valant, L. Aurelio, V.B. Urmaliya, P. White, P.J. Scammells, P.M. Sexton, and A. Christopoulos Mol. Pharmacol. 78 2010 444
16. S.R. Childers, X. Li, R. Xiao, and J.C. Eisanach J. Neurochem. 93 2005 715
17. A. Göblyös, and A.P. IJzerman Purinergic Signalling 5 2009 51
18. X. Li, D. Conklin, H.-L. Pan, and J.C. Eisenach J. Pharmacol. Exp. Ther. 305 2003 950
19. J.P. Conn, A. Christopoulos, and C.W. Lindsley Nat. Rev. Drug Disc. 8 2009 41
20. X. Li, D. Conklin, W. Ma, X. Zhu, and J.C. Eisenach Pain 97 2002 117
21. R. Romagnoli, P.G. Baraldi, M. Aghazadeh Tabrizi, S. Gessi, P.A. Borea, and S. Merighi Curr. Med. Chem. 17 2010 3488
22. A.P. IJzerman, A. Kouronakis, and P. Van der Klein Il Farmaco 56 2001 67
23. P.G. Baraldi, A.R. Moorman, M. Aghazadeh Tabrizi, M.G. Pavani, and R. Romagnoli Expert Opin. Ther. Pat. 14 2004 71
24. P.G. Baraldi, M.A. Iaconinoto, A.R. Moorman, M.D. Carrion, C.L. Cara, D. Preti, O.C. López, F. Fruttarolo, M.A. Tabrizi, and R. Romagnoli Mini-Rev. Med. Chem. 7 2007 559
25. Z.-G. Gao, S.-K. Kim, A.P. Ijzerman, and K.A. Jacobson Mini-Rev. Med. Chem. 5 2005 545
26. R.F. Bruns, and J.H. Fergus Mol. Pharmacol. 38 1990 939
27. R.F. Bruns, J.H. Fergus, L.L. Coughenour, G.G. Courtland, T.A. Pugsley, J.H. Dodd, and F.J. Tinney Mol. Pharmacol. 38 1990 950
28. P.A.M. Van der Klein, A.P. Kourounakis, and A.P. IJzerman J. Med. Chem. 42 1999 3629
29. P.G. Baraldi, A.N. Zaid, I. Lampronti, F. Fruttarolo, M.G. Pavani, M.A. Tabrizi, J.C. Shryock, E. Leung, and R. Romagnoli Bioorg. Med. Chem. Lett. 1953 2000 10
30. A.P. Kourounakis, P.A.M. van der Klein, and A.P. IJzerman Drug Dev. Res. 49 2000 227
31. C.E. Tranberg, A. Zickgraf, B.N. Giunta, H. Luetjens, H. Figler, L.J. Murphree, R. Falke, H. Fleischer, J. Linden, P.J. Scammells, and R.A. Olsson J. Med. Chem. 45 2002 382
32. H. Luetjens, A. Zickgraf, H. Figler, J. Linden, R.A. Olsson, and P.J. Scammells J. Med. Chem. 1870 2003 46
33. L. Aurelio, H. Figler, B.L. Flynn, J. Linden, and P.J. Scammells Bioorg. Med. Chem. 16 2008 1319
34. L. Aurelio, C. Valant, P.M. Sexton, A. Christopoulos, and P.J. Scammells J. Med. Chem. 52 2009 4543
35. C. Valant, L. Aurelio, S.M. Devine, T.D. Ashton, J.M. White, P.M. Sexton, A. Christopoulos, and P.J. Scammells J. Med. Chem. 55 2012 2367
36. R. Romagnoli, P.G. Baraldi, M.D. Carrion, C. Lopez-Cara, O. Cruz-Lopez, M.A. Iaconinoto, D. Preti, J.C. Shryock, A.R. Moorman, F. Vincenzi, K. Varani, and P.A. Borea J. Med. Chem. 51 2008 5875
37. For recent review articles based on the Gewald reaction see: Y. Huang, and A. Domling Mol. Diversity 15 2011 3
38. K. Wang, D. Kim, and A. Domling J. Comb. Chem. 12 2010 111
39. N. Miyaura, and A. Suzuki Chem. Rev. 95 1995 2457
40. S. Kotha, K. Lahiri, and D. Kashinath Tetrahedron 58 2002 9633
41. C.A. Kollias-Baker, J. Ruble, M. Jacobson, J.K. Harrison, M.J. Ozeck, J.C. Shryock, and L. Belardinelli J. Pharmacol. Exp. Ther. 281 1997 761
42. S. Bhattacharya, and J. Linden Mol. Pharmacol. 50 1996 104
43. 1 receptors by PD 81,723 only of 42 ± 7%, when tested at 100 μM. We speculate that species differences in affinity binding of PD 81,723 may explain the discrepancy between the data.
44. M.M. Bradford Anal. Biochem. 72 1976 248
45. P.G. Baraldi, R. Romagnoli, M.G. Pavani, M.C. Nuñez, M.A. Tabrizi, J.C. Shryock, E. Leung, A.R. Moorman, C. Uluoglu, V. Iannotta, S. Merighi, and P.A. Borea J. Med. Chem. 46 2003 794
46. P.A. Borea, A. Dalpiaz, K. Varani, S. Gessi, and G. Gilli Life Sci. 59 1996 1373
47. P.A. Borea, A. Dalpiaz, K. Varani, S. Gessi, and G. Gilli Biochem. Pharmacol. 49 1995 461
48. K. Varani, S. Merighi, S. Gessi, K.N. Klotz, E. Leung, P.G. Baraldi, B. Cacciari, R. Romagnoli, G. Spalluto, and P.A. Borea Mol. Pharmacol. 57 2000 968
49. P.J. Munson, and D. Rodbard Anal. Biochem. 107 1980 220
50. Y. Cheng, and W.H. Prusoff Biochem. Pharmacol. 1 1973 3099